BlackRock, Inc. Amends Schedule 13G for Aquestive Therapeutics Inc.

BlackRock, Inc. has filed an amendment to its Schedule 13G for Aquestive Therapeutics Inc., reporting ownership of 6,426,343 shares of common stock, representing 5.3% of the total outstanding shares. The filing indicates that BlackRock, Inc. has sole voting power over 6,290,838 shares and sole dispositive power over all 6,426,343 shares. The amendment reflects changes in ownership and is filed in accordance with SEC Release No. 34-39538. The filing also includes certifications that the securities were acquired and are held in the ordinary course of business and not for the purpose of influencing the control of the issuer.